name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
A119S	g.G355T	p.A119S			28628	N	N	MISSENSE	229	230	0						0	T=229	229	T	G						False	P.2	P.2=True	de_escalated	17-Mar-2021		
A33S	g.G97T	p.A33S			25489	ORF3a	ORF3a	MISSENSE	230	230	0						215	T=15	15	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A3686T	g.G11056A	p.A3686T			11321	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		215	A=15	15	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A3688V	g.C11063T	p.A3688V			11328	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40	T=190	190	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
A4771V	g.C14312T	p.A4771V			14576	ORF1ab	ORF1b	MISSENSE	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		225	T=5	5	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A4792A	g.A14376G	p.A4792A			14640	ORF1ab	ORF1b	SILENT	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		226	G=4	4	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A498A	g.A1494G	p.A498A			1759	ORF1ab	ORF1a	SILENT	230	230	0			nsp2	produced by both pp1a and pp1ab		227	G=3	3	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A6044V	g.C18131T	p.A6044V			18395	ORF1ab	ORF1b	MISSENSE	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		226	T=4	4	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A6623V	g.C19868T	p.A6623V			20132	ORF1ab	ORF1b	MISSENSE	230	230	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
A668V	g.C2003T	p.A668V			2268	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp2	produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
C2445C	g.C7335T	p.C2445C			7600	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		224	T=6	6	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
C6135C	g.T18405C	p.C6135C			18669	ORF1ab	ORF1b	SILENT	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		228	C=2	2	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D1036G	g.A3107G	p.D1036G			3372	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		202	G=28	28	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D1167D	g.T3501C	p.D1167D			3766	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		28	C=202	202	C	T						False	P.2	P.2=True	de_escalated	17-Mar-2021		
D128D	g.C384T	p.D128D			28657	N	N	SILENT	229	230	0						226	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D3439D	g.C10317T	p.D3439D			10582	ORF1ab	ORF1a	SILENT	230	230	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D3936D	g.C11808T	p.D3936D			12073	ORF1ab	ORF1a	SILENT	230	230	0			nsp7	produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D6097D	g.C18291T	p.D6097D			18555	ORF1ab	ORF1b	SILENT	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'E484K', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	229	230	0						0	G=229	229	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
D69D	g.C207T	p.D69D			27600	ORF7a	ORF7a	SILENT	230	230	0						40	T=190	190	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D614G', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	229	230	0						0	A=229	229	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	P.2	P.2=True	de_escalated	17-Mar-2021		
E6017E	g.G18051A	p.E6017E			18315	ORF1ab	ORF1b	SILENT	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		227	A=3	3	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
F120F	g.C360T	p.F120F			28251	ORF8	ORF8	SILENT	229	230	0						0	TTTA=226	226	TTTA	TTCA						False	P.2	P.2=True	de_escalated	17-Mar-2021		
F231S	g.T692C	p.F231S			26084	ORF3a	ORF3a	MISSENSE	224	230	0						137	C=87	87	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
F274F	g.C822T	p.F274F			29095	N	N	SILENT	230	230	0						228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
F32F	g.C96T	p.F32F			21658	S	S	SILENT	229	230	0	caution	ambiguous				225	T=4	4	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
FI120VL	g.TTCA358_361GTTC	p.FI120VL			28251	ORF8	ORF8		229	230	0						0	GTTC=2	2	GTTC	TTCA						False	P.2	P.2=False	de_escalated	17-Mar-2021		
G146D	g.G437A	p.G146D			702	ORF1ab	ORF1a	MISSENSE	230	230	0			leader protein	nsp1, produced by both pp1a and pp1ab		221	A=9	9	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
G4233G	g.A12699G	p.G4233G			12964	ORF1ab	ORF1a	SILENT	230	230	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		0	G=230	230	G	A						False	P.2	P.2=True	de_escalated	17-Mar-2021		
G442S	g.G1324A	p.G442S			1589	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp2	produced by both pp1a and pp1ab		224	A=6	6	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
G6953G	g.G20859T	p.G6953G			21123	ORF1ab	ORF1b	SILENT	227	230	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		225	T=2	2	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
H1545H	g.C4635T	p.H1545H			4900	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
H1652H	g.C4956T	p.H1652H			5221	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
H3125Y	g.C9373T	p.H3125Y			9638	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
H3H	g.T9C	p.H3H			27210	ORF6	ORF6	SILENT	230	230	0						226	C=4	4	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
I3853I	g.C11559T	p.I3853I			11824	ORF1ab	ORF1a	SILENT	230	230	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
I4049V	g.A12145G	p.I4049V			12410	ORF1ab	ORF1a	MISSENSE	229	230	0			nsp8	produced by both pp1a and pp1ab		220	G=9	9	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
I4205I	g.C12615T	p.I4205I			12880	ORF1ab	ORF1a	SILENT	230	230	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		225	T=5	5	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
K15K	g.G45A	p.K15K			26567	M	M	SILENT	221	230	0						206	A=15	15	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
K282K	g.G846A	p.K282K			1111	ORF1ab	ORF1a	SILENT	230	230	0			nsp2	produced by both pp1a and pp1ab		227	A=3	3	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
K65K	g.A195G	p.K65K			28468	N	N	SILENT	229	230	0						220	G=9	9	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L139F	g.G417T	p.L139F			28690	N	N	MISSENSE	229	230	0						227	T=2	2	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L161F	g.C481T	p.L161F			28754	N	N	MISSENSE	230	230	0						228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L3338L	g.C10014T	p.L3338L			10279	ORF1ab	ORF1a	SILENT	230	230	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L3468V	g.T10402G	p.L3468V			10667	ORF1ab	ORF1a	MISSENSE	230	230	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		0	G=230	230	G	T						False	P.2	P.2=True	de_escalated	17-Mar-2021		
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	230	230	0	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		226	T=4	4	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L3930F	g.C11788T	p.L3930F			12053	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp7	produced by both pp1a and pp1ab		0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
L4184L	g.C12550T	p.L4184L			12815	ORF1ab	ORF1a	SILENT	230	230	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L4I	g.C10A	p.L4I			275	ORF1ab	ORF1a	MISSENSE	230	230	0			leader protein	nsp1, produced by both pp1a and pp1ab		228	A=2	2	A	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	229	230	0	mask	highly_homoplasic				225	T=4	4	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	229	230	0	mask	highly_homoplasic				225	T=4	4	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	229	230	0	mask	highly_homoplasic				225	T=4	4	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
L6848L	g.C20542T	p.L6848L			20806	ORF1ab	ORF1b	SILENT	227	230	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		225	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
M234I	g.G702T	p.M234I			28975	N	N	MISSENSE	230	230	0						0	T=230	230	T	G						False	P.2	P.2=True	de_escalated	17-Mar-2021		
M322L	g.A964T	p.M322L			29237	N	N	MISSENSE	230	230	0						222	T=8	8	T	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
N257N	g.T771C	p.N257N			26163	ORF3a	ORF3a	SILENT	226	230	0						223	C=3	3	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
N3501N	g.T10503C	p.N3501N			10768	ORF1ab	ORF1a	SILENT	230	230	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		228	C=2	2	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
N8Y	g.A22T	p.N8Y			28295	N	N	MISSENSE	229	230	0						227	T=2	2	T	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
N99N	g.C297T	p.N99N			21859	S	S	SILENT	230	230	0						215	T=15	15	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P104L	g.C311T	p.P104L			25703	ORF3a	ORF3a	MISSENSE	230	230	0						218	T=12	12	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P1054L	g.C3161T	p.P1054L			3426	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		220	T=10	10	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P2605S	g.C7813T	p.P2605S			8078	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		69	T=161	161	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P3272P	g.A9816G	p.P3272P			10081	ORF1ab	ORF1a	SILENT	230	230	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		224	G=6	6	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P361L	g.C1082T	p.P361L			1347	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp2	produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P4715L	g.C14144T	p.P4715L			14408	ORF1ab	ORF1b	MISSENSE	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
P626P	g.C1878T	p.P626P			2143	ORF1ab	ORF1a	SILENT	230	230	0			nsp2	produced by both pp1a and pp1ab		226	T=4	4	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P665P	g.C1995T	p.P665P			23557	S	S	SILENT	229	230	0						143	T=86	86	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
P971L	g.C2912T	p.P971L			3177	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
Q260H	g.A780T	p.Q260H			29053	N	N	MISSENSE	230	230	0						228	T=2	2	T	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
Q4884Q	g.A14652G	p.Q4884Q			14916	ORF1ab	ORF1b	SILENT	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		228	G=2	2	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
R1170C	g.C3508T	p.R1170C			3773	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
R1386R	g.C4158T	p.R1386R			4423	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
R24R	g.C72T	p.R24R			337	ORF1ab	ORF1a	SILENT	230	230	0			leader protein	nsp1, produced by both pp1a and pp1ab		221	T=9	9	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
R4723R	g.A14169G	p.R4723R			14433	ORF1ab	ORF1b	SILENT	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		228	G=2	2	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
RG203KR	g.GGG608_610AAC	p.RG203KR			28881	N	N		230	230	0						0	AAC=230	230	AAC	GGG						False	P.2	P.2=True	de_escalated	17-Mar-2021		
S272S	g.C816T	p.S272S			26208	ORF3a	ORF3a	SILENT	225	230	0						223	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S327L	g.C980T	p.S327L			29253	N	N	MISSENSE	229	230	0						221	T=8	8	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S391F	g.C1172T	p.S391F			1437	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp2	produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S4398L	g.C13193T	p.S4398L			13458	ORF1ab	ORF1a	MISSENSE	229	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		227	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S45F	g.C134T	p.S45F			21696	S	S	MISSENSE	230	230	0						228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S4621G	g.A13861G	p.S4621G			14125	ORF1ab	ORF1b	MISSENSE	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		227	G=3	3	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S5393N	g.G16178A	p.S5393N			16442	ORF1ab	ORF1b	MISSENSE	229	230	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		227	A=2	2	A	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S549S	g.C1647T	p.S549S			1912	ORF1ab	ORF1a	SILENT	230	230	0			nsp2	produced by both pp1a and pp1ab		227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S54L	g.C161T	p.S54L			28054	ORF8	ORF8	MISSENSE	229	230	0						226	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
S60S	g.C180A	p.S60S			21742	S	S	SILENT	229	230	0						211	A=18	18	A	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T1890T	g.A5670G	p.T1890T			5935	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		224	G=6	6	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T20T	g.C60T	p.T20T			21622	S	S	SILENT	230	230	0						227	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T2186A	g.A6556G	p.T2186A			6821	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		98	G=132	132	G	A						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T2280I	g.C6839T	p.T2280I			7104	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T2495I	g.C7484T	p.T2495I			7749	ORF1ab	ORF1a	MISSENSE	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T4066I	g.C12197T	p.T4066I			12462	ORF1ab	ORF1a	MISSENSE	229	230	0			nsp8	produced by both pp1a and pp1ab		227	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T4418I	g.C13253T	p.T4418I			13517	ORF1ab	ORF1b	MISSENSE	229	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		226	T=3	3	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T5195I	g.C15584T	p.T5195I			15848	ORF1ab	ORF1b	MISSENSE	229	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		224	T=5	5	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T572I	g.C1715T	p.T572I			23277	S	S	MISSENSE	229	230	0						223	T=6	6	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T6028T	g.C18084T	p.T6028T			18348	ORF1ab	ORF1b	SILENT	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T6131T	g.C18393T	p.T6131T			18657	ORF1ab	ORF1b	SILENT	230	230	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		228	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T6550T	g.T19650C	p.T6550T			19914	ORF1ab	ORF1b	SILENT	230	230	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		228	C=2	2	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	230	230	0						227	T=3	3	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	230	230	0						227	T=3	3	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	230	230	0						227	T=3	3	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.2	P.2=False	de_escalated	17-Mar-2021		
V1176F	g.G3526T	p.V1176F			25088	S	S	MISSENSE	230	230	0						0	T=230	230	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'E484K', 'D614G'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.2	P.2=True	de_escalated	17-Mar-2021		
V4816L	g.G14446T	p.V4816L			14710	ORF1ab	ORF1b	MISSENSE	230	230	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		98	T=132	132	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
V6536V	g.G19608T	p.V6536V			19872	ORF1ab	ORF1b	SILENT	230	230	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		227	T=3	3	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
Y1007Y	g.T3021C	p.Y1007Y			24583	S	S	SILENT	230	230	0						224	C=6	6	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
Y860Y	g.T2580C	p.Y860Y			2845	ORF1ab	ORF1a	SILENT	230	230	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		228	C=2	2	C	T						False	P.2	P.2=False	de_escalated	17-Mar-2021		
g.C-166T	g.C-166T				100	ORF1ab	intergenic		230	230	0						0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
g.C-25T	g.C-25T				241	ORF1ab	intergenic		230	230	0						0	T=230	230	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
g.C29754T	g.C29754T				29754	intergenic	intergenic		37	230	0						0	T=37	37	T	C						False	P.2	P.2=True	de_escalated	17-Mar-2021		
g.C29762T	g.C29762T				29762	intergenic	intergenic		37	230	0						35	T=2	2	T	C						False	P.2	P.2=False	de_escalated	17-Mar-2021		
g.G-56T	g.G-56T				210	ORF1ab	intergenic		230	230	0						226	T=4	4	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
g.G29781T	g.G29781T				29781	intergenic	intergenic		37	230	0						36	T=1	1	T	G						False	P.2	P.2=False	de_escalated	17-Mar-2021		
